1. Home
  2. CTMX vs KPTI Comparison

CTMX vs KPTI Comparison

Compare CTMX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • KPTI
  • Stock Information
  • Founded
  • CTMX 2008
  • KPTI 2008
  • Country
  • CTMX United States
  • KPTI United States
  • Employees
  • CTMX N/A
  • KPTI N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTMX Health Care
  • KPTI Health Care
  • Exchange
  • CTMX Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • CTMX 62.3M
  • KPTI 81.1M
  • IPO Year
  • CTMX 2015
  • KPTI 2013
  • Fundamental
  • Price
  • CTMX $0.80
  • KPTI $0.62
  • Analyst Decision
  • CTMX Buy
  • KPTI Strong Buy
  • Analyst Count
  • CTMX 6
  • KPTI 4
  • Target Price
  • CTMX $5.77
  • KPTI $5.00
  • AVG Volume (30 Days)
  • CTMX 731.5K
  • KPTI 768.4K
  • Earning Date
  • CTMX 03-10-2025
  • KPTI 02-19-2025
  • Dividend Yield
  • CTMX N/A
  • KPTI N/A
  • EPS Growth
  • CTMX N/A
  • KPTI N/A
  • EPS
  • CTMX 0.16
  • KPTI N/A
  • Revenue
  • CTMX $126,617,000.00
  • KPTI $148,442,000.00
  • Revenue This Year
  • CTMX $22.55
  • KPTI $4.47
  • Revenue Next Year
  • CTMX N/A
  • KPTI $7.35
  • P/E Ratio
  • CTMX $4.93
  • KPTI N/A
  • Revenue Growth
  • CTMX 33.66
  • KPTI 1.77
  • 52 Week Low
  • CTMX $0.75
  • KPTI $0.58
  • 52 Week High
  • CTMX $5.85
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 41.61
  • KPTI 43.29
  • Support Level
  • CTMX $0.75
  • KPTI $0.58
  • Resistance Level
  • CTMX $0.98
  • KPTI $0.67
  • Average True Range (ATR)
  • CTMX 0.06
  • KPTI 0.05
  • MACD
  • CTMX 0.00
  • KPTI -0.00
  • Stochastic Oscillator
  • CTMX 20.13
  • KPTI 31.02

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: